<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836638</url>
  </required_header>
  <id_info>
    <org_study_id>USJ-09</org_study_id>
    <nct_id>NCT03836638</nct_id>
  </id_info>
  <brief_title>The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment</brief_title>
  <official_title>The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Joseph University, Beirut, Lebanon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Joseph University, Beirut, Lebanon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are&#xD;
      usually older than 45 years and their main demand is to treat pre-existing facial wrinkles.&#xD;
      However with the increasing popularity of this technique, younger patients, aged 25 to 35&#xD;
      years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The&#xD;
      usual dose used for the treatment of facial rhytides in a female patient older than 45 years&#xD;
      is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used&#xD;
      in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and&#xD;
      long lasting results in young patients. The objective of this randomized open-label study is&#xD;
      to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are&#xD;
      usually older than 45 years and their main demand is to treat pre-existing facial wrinkles.&#xD;
      However with the increasing popularity of this technique, younger patients, aged 25 to 35&#xD;
      years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The&#xD;
      usual dose used for the treatment of facial rhytides in a female patient older than 45 years&#xD;
      is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used&#xD;
      in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and&#xD;
      long lasting results in young patients.&#xD;
&#xD;
      The objective of this randomized open-label study is to evaluate the effect of lower doses of&#xD;
      Botulinum toxin on the facial rythides in young patients.&#xD;
&#xD;
      In this trial, patients will be divided into 3 groups: Group 1 patients will be 25-35 years&#xD;
      old and will be injected with 30 units of botulinum toxin into the upper face, group 2&#xD;
      patients will be older than 45 and will be injected with the same amount of botulinum toxin&#xD;
      into the upper face and group 3 patients will be older than 45 and will be treated with the&#xD;
      usual 50 units dose (control group). Patients older than 45 will be randomized between groups&#xD;
      2 and 3. Validated photonumeric scales will be used to evaluate the wrinkles at rest and with&#xD;
      muscle contraction at 2, 4, 8, 12, 16, 20, 24 weeks post injection in the 3 groups. The&#xD;
      patient satisfaction rate and the Physician global assessment will also be evaluated in the 3&#xD;
      groups. The scores will be determined by 3 independent blinded raters.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      (1) the low dose will be sufficient to treat the group 1 patients and it will be insufficient&#xD;
      to treat the group 2 patients. (2) The results will last longer in groups 1 and 3 patients&#xD;
      compared to group 2 patients. (3) Group 1 patients treated with low doses of botulinum toxin&#xD;
      will have similar results to the group 3 patients treated with the standard dose of botulinum&#xD;
      toxin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Brow Positioning Scale at rest</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-Youthful, refreshed look and high-arch eyebrow&#xD;
Medium-arch eyebrow&#xD;
Slight arch of the eyebrow&#xD;
Flat arch of the eyebrow, visibility of folds, and tired appearance&#xD;
Flat eyebrow with barely any arch, marked visibility of folds, and very tired appearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Forehead Lines Scale at rest</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-None&#xD;
Minimal&#xD;
Moderate&#xD;
Deep&#xD;
Extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Forehead Lines Scale with contraction</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-None&#xD;
Minimal&#xD;
Moderate&#xD;
Deep&#xD;
Extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Glabellar Lines Scale at rest</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-No glabella lines&#xD;
Mild glabella lines&#xD;
Moderate glabella lines&#xD;
Severe glabella lines&#xD;
Very severe glabella lines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Glabellar Lines Scale with contraction</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-No glabella lines&#xD;
Mild glabella lines&#xD;
Moderate glabella lines&#xD;
Severe glabella lines&#xD;
Very severe glabella lines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Crow Feet Scale at rest</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-No wrinkles&#xD;
Mild wrinkles&#xD;
Moderate wrinkles&#xD;
Severe wrinkles&#xD;
Very severe wrinkles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of scores of Validated photonumeric scales: Crow Feet Scale with contraction</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>0-No wrinkles&#xD;
Mild wrinkles&#xD;
Moderate wrinkles&#xD;
Severe wrinkles&#xD;
Very severe wrinkles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigators Global Aesthetic Improvement Scale</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>Very Much Improved: optimal cosmetic results&#xD;
Much Improved: marked improvement in appearance from initial condition but not completely optimal&#xD;
Improved: obvious improvement in appearance from initial condition but additional treatments are advised&#xD;
No Change: the appearance is the same as the original condition&#xD;
Worse: the appearance is worse from the original condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>0, 2, 4, 8, 12, 16, 20, 24 weeks</time_frame>
    <description>Very Satisfied&#xD;
Satisfied&#xD;
Dissatisfied&#xD;
Very Dissatisfied.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Aging</condition>
  <condition>Botulinum Toxin</condition>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>Low dose young subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose older subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose older subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 Units of botulinum toxin</intervention_name>
    <description>30 Units of botulinum toxin to upper face</description>
    <arm_group_label>Low dose older subjects</arm_group_label>
    <arm_group_label>Low dose young subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 Units of botulinum toxin</intervention_name>
    <description>50 Units of botulinum toxin to upper face</description>
    <arm_group_label>high dose older subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female patients presenting to our clinic for Facial wrinkle treatment with botulinum&#xD;
             toxin&#xD;
&#xD;
          -  Must be between 25-35 years old to be included in group 1.&#xD;
&#xD;
          -  Must be older than 45 to be included in groups 2 and 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous periorbital/forehead surgery&#xD;
&#xD;
          -  Patients who plucked the upper eyebrow margin&#xD;
&#xD;
          -  Patients with eyebrow tatoos&#xD;
&#xD;
          -  Patients with upper face botulinum toxin injection in the past 12 months&#xD;
&#xD;
          -  Patients with resorbable upper face fillers injection in the past 12 months&#xD;
&#xD;
          -  Patients with previous permanent upper face fillers injection&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Lactating patients&#xD;
&#xD;
          -  Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert&#xD;
             syndrome)&#xD;
&#xD;
          -  Patients using medication that could potentiate the effect of botulinum (ex:&#xD;
             aminoglycoside antibiotics)&#xD;
&#xD;
          -  Patients with sensitivity to botulinum toxin or human albumin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hotel Dieu De France</name>
      <address>
        <city>Beirut</city>
        <state>Aschrafieh</state>
        <zip>00961</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Joseph University, Beirut, Lebanon</investigator_affiliation>
    <investigator_full_name>samer jabbour</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Botulinum Toxin</keyword>
  <keyword>Rejuvenation</keyword>
  <keyword>Age</keyword>
  <keyword>Wrinkles</keyword>
  <keyword>Rhytidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

